Certara Endows Lectureship in Precision Dosing at The University of Manchester, England
PRINCETON, NJ – June 3, 2015 – Certara®, the global biosimulation technology-enabled drug development consultancy, today announced that it is endowing a new three-year, full-time position – the Certara Lecturer in Precision Dosing – at the Manchester Pharmacy School, The University of Manchester, England. This lectureship is intended to advance teaching and research into individual dose optimization modeling, and to demonstrate its application to cancer, pediatric, and biologic therapies.
This new lecturer will work closely with the clinical pharmacy, clinical pharmacology, and quantitative proteomics research groups at The University of Manchester to raise the profile of precision dosing within the university’s precision medicine initiative. This staff member will also lead post-graduate modeling and simulation programs.
“Our work with global biopharm companies and regulatory agencies demonstrates the advantages of using biosimulation to answer precision dosing questions for specific cohorts such as pediatric or geriatric patients, women who are pregnant, or patients with co-morbidities,” said Certara Chief Executive Officer Edmundo Muniz, M.D., Ph.D. “Through this new academic collaboration with The University of Manchester, we expect to further the field and make precision dosing for all individuals a reality.”
“Precision medicine has the potential to improve dramatically the healthcare outcomes for individual patients around the world,” added Professor Kay Marshall B.Pharm., FRPharm.S., PhD., MBA, head of Manchester Pharmacy School. “We are delighted to have this opportunity to partner with Certara and help prepare our students for exciting pharmacometric careers by providing them with individual dose optimization modeling experience.”
This new lecturer will become a member of the Systems Pharmacology Group within Manchester Pharmacy School. The postholder will report to the Head of School and be mentored by Professor Amin Rostami, Pharm.D., Ph.D., professor of systems pharmacology at The University of Manchester, and Certara’s Chief Scientific Officer.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Phase II ALPACA Trial Shows Lepodisiran Produces Significant, Sustained Lipoprotein(a) Reductions
March 31st 2025Eli Lilly’s lepodisiran, an investigational siRNA therapy, achieved significant and durable reductions in lipoprotein(a) levels, a major genetic risk factor for cardiovascular disease.
